BDSX — Biodesix Income Statement
0.000.00%
Last trade - 00:00
- $256.96m
- $250.59m
- $49.09m
- 32
- 16
- 74
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 24.6 | 45.6 | 54.5 | 38.2 | 49.1 |
Cost of Revenue | |||||
Gross Profit | 18.5 | 23.6 | 24 | 24.1 | 36.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 51.3 | 68.5 | 93.1 | 95.8 | 90.4 |
Operating Profit | -26.7 | -22.9 | -38.6 | -57.6 | -41.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30.7 | -31.4 | -43.2 | -65.4 | -52.1 |
Net Income After Taxes | -30.7 | -31.4 | -43.2 | -65.4 | -52.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -30.7 | -31.4 | -43.2 | -65.4 | -52.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.7 | -31.4 | -43.2 | -65.4 | -52.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.04 | -1.15 | -1.66 | -1.39 | -0.635 |
Dividends per Share |